Dopamine depletion alters responses to glutamate and GABA in the rat subthalamic nucleus

NeuroReport

Volumn 16, Issue 2, 2005, Pages 171-174

  Shen, Ke Zhong ^a   Johnson, Steven W ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

6 OHDA; AMPA; Baclofen; Brain slice; Isoguvacine; NMDA

Indexed keywords

4 AMINOBUTYRIC ACID; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; AMPA RECEPTOR; ARECAIDINE; BACLOFEN; DESIPRAMINE; DOPAMINE; GLUTAMIC ACID; IONOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; OXIDOPAMINE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; MALE; MOTOR PERFORMANCE; NERVE CONDUCTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION;

ANIMALS; DOPAMINE; GABA AGONISTS; GLUTAMIC ACID; MALE; OXIDOPAMINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GABA; RECEPTORS, GLUTAMATE; SUBTHALAMIC NUCLEUS;

EID: 13844251858     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200502080-00021     Document Type: Article

References (25)

1. Parent A and Hazrati L-N. Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidium in basal ganglia circuitry. Brain Res Rev 1995; 20:128-154.
2. DeLong MR. Primate models of movement disorders of basal ganglia origin. Trend Neurosci 1990; 13:281-285.
3. Miller WC and DeLong MR. Parkinsonian symptomatology. An anatomical and physiological analysis. Ann NY Acad Sci 1988; 515:287-302.
4. Tremblay M, Salin P and Soghomonian JJ. Effect of 6-OHDA lesions on striatal mRNA levels encoding for glutamate receptor subunits. Neuroreport 1995; 6:2225-2229.
5. Betarbet R, Porter RH and Greenamyre JT. GluR1 glutamate receptor subunit is regulated differentially in the primate basal ganglia following nigrostriatal dopamine denervation. J Neurochem 2000; 74:1166-1174.
6. Wullner U, Testa CM, Catania MV, Young AB and Penney JB, Jr. Glutamate receptors in striatum and substantia nigra: effects of medial forebrain bundle lesions. Brain Res 1994; 645:98-102.
7. Dunah AW, Wang Y, Yasuda RP, Kameyama K, Huganir RL, Wolfe BB and Standaert DG. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 2000; 57:342-352.
8. Oh JD, Russell D, Vaughan CL and Chase TN. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res 1998; 813:150-159.
9. Betarbet R, Poisik O, Sherer TB and Greenamyre JT. Differential expression and ser897 phosphorylation of striatal N-methyl-D-aspartate receptor subunit NR1 in animal models of Parkinson's disease. Exp Neurol 2004; 187:76-85.
10. A receptor subunit gene expression in the rodent basal ganglia and thalamus. Neuroscience 2000; 95:119-126.
11. A receptors in rat neostriatum, cortex, and thalamus after neonatal 6-hydroxydopamine lesion. J Neurochem 1993; 60:936-945.
12. Segovia J, Armstrong DM, Benzing WC and Hornby PJ. Striatal glutamic acid decarboxylase immunoreactivity is increased after dopaminergic deafferentation: densitometric analysis. Neurosci Lett 1991; 122:252-256.
13. Schlosser B, Muller A, Sutor B and Bruggencate GT. 1-Methyl-4-phenyl-1,2, 3,6-tetrahydropyridine-induced dopaminergic denervation potentiates GABAergic inhibition in the mouse neostriatum in vitro. Neuroscience 1996; 71:691-700.
14. 2 subunits and metabotropic glutamate receptor 5 in the basal ganglia of the rats with unilateral 6-hydroxydopamine lesion and embryonic mesencephalic grafts. Exp Neurol 2001; 168:231-241.
15. Porter RH, Greene JG, Higgins DS Jr and Greenamyre JT. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J Neurosci 1994; 14:7192-7199.
16. 1 receptors regulate synaptic transmission to rat substantia nigra reticulata neurones. J Physiol (Lond) 1997; 505:153-163.
17. Albin RL, Makowiec RL, Hollingsworth ZR, Dure LS, IV, Penney JB and Young AB. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience 1991; 46:35-48.
18. Blandini F, Nappi G and Greenamyre JT. Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 2001; 49:525-529.
19. Götz T, Kraushaaar U, Geiger J, Lübke J, Berger T and Jonas P. Functional properties of AMPA and NMDA receptors expressed in identified types of basal ganglia neurons. J Neurosci 1997; 17:204-215.
20. Zhu Z-T, Munhall A, Shen K-Z and Johnson SW. Calcium dependent subthreshold oscillations determine bursting activity induced by N-methyl-D-aspartate in rat subthalamic neurons in vitro. Eur J Neurosci 2004; 19:1296-1304.
21. Bergman H, Wichmann T, Karmon B and DeLong MR. The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 1994; 72:507-520.
22. Johnston T and Duty S. Changes in GABA-B receptor mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway. Neurosci 2003; 120:1027-1035.
23. Mitchell IJ, Clarke CE, Boyce S, Robertson RG, Peggs D, Sambrook MA and Crossman AR. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine. Neuroscience 1989; 32:213-226.
24. Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B and Wichmann T. Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 2004; 24:6417-6426.
25. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Movement Dis 2004; 19:743-754.